111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 2041-2047

  Kahn, Daniel ^a   Williams, Richard D ^b   Manyak, Michael J ^b   Haseman, Michael K ^b   Seldin, David W ^b   Libertino, John A ^b   Maguire, Robert T ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

111Indium; Capromab pendetide; Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

CAPROMAB PENDETIDE IN 111; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; INDIUM;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SCINTISCANNING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; BLOOD; DISEASE COURSE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PROSTATE TUMOR; RADIOIMMUNOASSAY; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; HUMANS; INDIUM RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION;

EID: 0032091741     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63239-7     Document Type: Article

References (26)

1. Mettlin, C., Jones, G. W. and Murphy, G. P.: Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA, 43: 83, 1993.
2. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
3. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
4. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol., 149: 516, 1993.
5. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynec. Oncol., 48: 285, 1993.
6. Collier, B. D., Abdel-Nabi, H., Doerr, R. J., Harwood, S. J., Olsen, J., Kaplan, E. H., Winzelberg, G. G., Grossman, S. J., Kran, D. N. and Mitchell, E. P.: Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology, 185: 179, 1992.
7. Oefelein, M. G., Smith, N., Carter, M., Dalton, D. and Schaeffer, A.: The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol., 154: 2128, 1995.
8. Wright, G. L., Haley, C., Beckett, M. L. and Schellhammer, P. F.: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol., 1: 18, 1995.
9. Wright, G. L., Jr., Grob, B. M., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F. and Moriarty, R.: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326, 1996.
10. Abdel-Nabi, H., Wright, G. L., Gulfo, J. V., Petrylak, D. P., Neal, C. E., Texter, J. E., Begun, F. P., Tyson, I., Heal, A., Mitchell, E., Purnell, G. and Harwood, S. J.: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Sem. Urol., 10: 45, 1992.
11. 111indium-labeled monoclonal antibody CYT-356. J. Urol., 152: 1952, 1994.
12. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol., 152: 1490, 1994.
13. Burgers, J. K., Hinkle, G. H. and Haseman, M. K.: Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Sem. Urol., 13: 103, 1995.
14. Rodwell, J. D., Alvarez, V. L., Lee, C., Lopes, A. D., Goers, J. W., King, H. D., Powsner, H. J. and McKearn, T. J.: Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc. Natl. Acad. Sci. U.S.A., 83: 2632, 1986.
15. Abi-Aad, A. S., MacFarlane, M. T., Stein, A. and deKernion, J. B.: Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J. Urol., 147: 952, 1992.
16. Lightner, D. J., Lange, P. H., Reddy, P. K. and Moore, L.: Prostate specific antigen and local recurrence after radical prostatectomy. J. Urol., 144: 921, 1990.
17. Foster, L. S., Jajodia, P., Fournier, G. Jr., Shinohara, K., Carroll, P. and Narayan, P.: The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J. Urol., 149: 1024, 1993.
18. Platt, J. F., Bree, R. L. and Schwab, R. E.: The accuracy of staging carcinoma of the prostate. AJR, 149: 315, 1987.
19. Tempany, C. M., Zhou, X., Zerhouni, E. A., Rifkin, M. D., Quint, L. E., Piccoli, C. W., Ellis, J. H. and McNeil, B. J.: Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology, 192: 47, 1994.
20. Elkin, M. and Mueller, H. P.: Metastases from cancer of the prostate. Cancer, 7: 1246, 1954.
21. Saitoh, H., Yoshida, K.-I., Uchijima, Y., Kobayashi, N., Suwata, J. and Kamata, S.: Two different lymph node metastatic patterns of a prostatic cancer. Cancer, 65: 1843, 1990.
22. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
23. Klein, E. A.: Management of elevated PSA after radical prostatectomy. J. Urol., part 2, 149: 349A, abstract 544, 1993.
24. Pilepich, M. V., Asbell, S. O., Krall, J. M., Baerwald, W. H., Sause, W. T., Rubin, P., Emami, B. N. and Pidcock, G. M.: Correlation of radiotherapeutic parameters and treatment related morbidity-analysis of RTOG study 77-06. Int. J. Rad. Oncol. Biol. Phys., 13: 1007, 1987.
25. Soffen, E. M., Hanks, G. E., Hunt, M. A. and Epstein, B. E.: Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int. J. Rad. Oncol. Biol. Phys., 24: 485, 1992.
26. Kahn, D., Williams, R. D. and Haseman, M. K.: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin. Oncol., 16: 284, 1998.